Equities

Financials data is unavailable for this security.

Inc stmt in EURIncome statement in EURView more

Year on year Bayer AG had relatively flat revenues (46.09bn to 46.77bn), though the company grew net income 10.24% from 4.11bn to 4.53bn. A reduction in the cost of goods sold as a percentage of sales from 45.65% to 43.39% was a component in the net income growth despite flat revenues.
Gross margin57.23%
Net profit margin10.80%
Operating margin16.28%
Return on assets6.43%
Return on equity16.72%
Return on investment8.57%
More ▼

Cash flow in EURView more

In 2016, Bayer AG did not generate a significant amount of cash. However, the company earned 9.09bn from its operations for a Cash Flow Margin of 19.44%. In addition the company used 8.73bn on investing activities and also paid 350.00m in financing cash flows.
Cash flow per share9.59
Price/Cash flow per share12.46
Book value per share40.65
Tangible book value per share4.79
More ▼

Balance sheet in EURView more

Bayer AG has a Debt to Total Capital ratio of 34.62%, a lower figure than the previous year's 72.46%.
Current ratio1.71
Quick ratio1.26
Total debt/total equity0.5648
Total debt/total capital0.3462
More ▼

Growth rates in EUR

Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 8.00% and 5.21%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth ranked highest relative to its industry peers, while earnings per share growth is in-line with the industry average.
Div yield(5 year avg)1.88%
Div growth rate (5 year)10.35%
Payout ratio (TTM)46.66%
EPS growth(5 years)11.38
EPS (TTM) vs
TTM 1 year ago
11.05
More ▼
© Thomson Reuters Click for restrictions
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.